NCT03976648View on ClinicalTrials.gov

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

April 13, 2021

Study Completion Date

April 13, 2021

Conditions
Systemic Sclerosis
Interventions
DRUG

GLPG1690

film-coated tablets of GLPG1690 to be administered orally

Trial Locations (14)

3000

UZ Leuven, Leuven

8035

Hospital Universitario Vall d'Hebron, Barcelona

9000

UZ Gent, Ghent

20132

Ospedale San Raffaele S.r.l. - PPDS, Milan

28041

Hospital Universitario 12 de Octubre, Madrid

33486

RASF Clinical Research Center, Boca Raton

48109

University of Michigan, Ann Arbor

50139

Azienda Ospedaliero Universitaria Careggi, Florence

75231

Metroplex Clinical Research Center, Dallas

77030

UT Physicians Center for Autoimmunity, Houston

90045

Pacific Arthritis Care Center, Los Angeles

90095

UCLA Rheumatology, Los Angeles

L9 7AL

University Hospital Aintree, Liverpool

NW32QG

Royal Free Hospital, London

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT03976648 - A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis | Biotech Hunter | Biotech Hunter